A Phase 1 interventional study of Apixaban in Thrombosis, sponsored by Bristol-Myers Squibb. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-03-03.
Sponsored by Bristol-Myers Squibb · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing apixaban in Thrombosis — 5 open to participants now, 5 under way, 2 of them phase 3. apixaban · Thrombosis.
Among the 18 studies testing apixaban in Thrombosis, this one is the 10th largest by enrollment, is one of 2 that started in 2014, is one of 4 in phase 1, and was the 2nd registered.
955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.
Browse Thrombosis studies →5 of the 18 studies testing apixaban in Thrombosis are open now, in 3 countries. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 18–80
Kiranya Arnold · Sites in United States
Ages 18–89
Rushad Patell · Sites in United States
Ages 18+
Queen Mary University of London · Sites in United Kingdom
Ages 16+
Clinical Urology and Epidemiology Working Group · Sites in Finland
Ages 18+
By country, each count listing its studies:
apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 4 · Phase 4 6
First in 2009; this study’s year is marked. 2 started in 2014.
This study's enrollment of 69 is below the median of 83 across 530 interventional studies indexed under Thrombosis.
Median enrollment 73 across the 18 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 18 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
19 studies in Thrombosis by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 19 finished, 7 (37%) have results posted.
Among the 19 studies in Thrombosis by Bristol-Myers Squibb, this one is the 8th largest by enrollment, is one of 2 that started in 2014, is one of 13 in phase 1, and was the 3rd registered.
Bristol-Myers Squibb’s Thrombosis studies by the year they started, since 2006.
2 of the studies testing apixaban in Thrombosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06886516Rushad PatellApixaban in Thrombocytopenia | 2027-07-01 |
| NCT07189897Kiranya ArnoldApixaban or Enoxaparin After Head and Neck Cancer Surgery | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies testing apixaban in Thrombosis, from their registry updates:
Among Bristol-Myers Squibb’s 19 in Thrombosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether the bioavailability of apixaban crushed tablets suspended in water or mixed with applesauce is similar to the bioavailability of apixaban whole tablets administered orally.
This study will investigate the bioavailability of apixaban administered as crushed tablets suspended in water and as crushed tablets mixed with applesauce compared with that of whole tablets. The study results may allow enhancement of the apixaban label to include alternative methods of apixaban administration, which may be of benefit to patients who have difficulty swallowing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Any laboratory test results outside of the range of normal, confirmed by repeat results of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single dose of apixaban, 10 mg, given orally as 2 5-mg whole commercial tablets (reference)
Drug: Apixaban
Participants received a single dose of apixaban, 10 mg, given by mouth as 2 5-mg whole commercial tablets crushed and suspended in 30 mL of water
Drug: Apixaban
Participants received a single dose of 10 mg, given by mouth as 2 5-mg apixaban commercial tablets crushed and mixed with 30 g of applesauce
Drug: Apixaban
Also known as: Eliquis®
Adjusted Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Apixaban
Maximum observed plasma concentration (Cmax) measured in nanograms per milliliter (ng/mL)
Time frame: Days 1, 5, and 9 predose and 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60 and 72 hours post dose
Adjusted Geometric Mean of Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Apixaban
Area Under the Plasma Concentration-time Curve (AUC) From Time of Zero Extrapolated to Infinite Time (INF) \[AUC (INF)\] is measured as nanograms multiplied by hours per milliliter (ng\*h/mL)
Time frame: Days 1, 5, and 9 predose and 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, and 72 hours post dose
Adjusted Geometric Mean of Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Last Quantifiable Concentration \[AUC (0-T)\] is measured as nanograms multiplied by hours per milliliter (ng\*h/mL)
Time frame: Days 1, 5, and 9 predose and 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, and 72 hours post dose
Number of Participants With Serious Adverse Events, Death, or Discontinuation Due to Adverse Events by Study Completion
Adverse Event (AE) = any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Serious Adverse Event (SAE)= a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Time frame: Randomization to May 2014; approximately 6 weeks
Time of Maximum Observed Plasma Concentration (Tmax) of Apixaban
Time of maximum observed plasma concentration (Tmax) measured in hours (h)
Time frame: Days 1, 5 and 9 pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12 24, 36, 48, 60 and 72 hrs post dose
Terminal Plasma Half-life (T-HALF) of Apixaban
Terminal plasma half-life (T-HALF) was derived from plasma concentration versus time data. T-HALF was the time required for one half of the total amount of administered drug to be eliminated from the body.
Time frame: Days 1, 5 and 9 pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12 24, 36, 48, 60 and 72 hrs post dose
Relative Bioavailability (Frel) of Apixaban
Frel is calculated using the treatment ratio of AUC(INF) where the denominator is the AUC(INF) of the reference therapy, 10mg of Apixaban (whole tablet).
Time frame: Days 1, 5 and 9 pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12 24, 36, 48, 60 and 72 hrs post dose
| Milestone | Treatment A Then Treatment B Then Treatment C | Treatment A Then Treatment C Then Treatment B | Treatment B Then Treatment C Then Treatment A | Treatment B Then Treatment A Then Treatment C | Treatment C Then Treatment A Then Treatment B | Treatment C Then Treatment B Then Treatment A |
|---|---|---|---|---|---|---|
| Started | 6 | 5 | 6 | 5 | 6 | 5 |
| Completed | 6 | 5 | 5 | 5 | 5 | 5 |
| Not completed | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 |
Maximum observed plasma concentration (Cmax) measured in nanograms per milliliter (ng/mL)
| ng/mL | Apixaban, 10 mg (Whole Tablets) | Apixaban, 10 mg (Crushed and Suspended in Water) | Apixaban, 10 mg (Crushed and Mixed With Applesauce) |
|---|---|---|---|
| Adjusted Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Apixaban | 236 (217 to 256) | 249 (232 to 266) | 186 (174 to 199) |
Area Under the Plasma Concentration-time Curve (AUC) From Time of Zero Extrapolated to Infinite Time (INF) \[AUC (INF)\] is measured as nanograms multiplied by hours per milliliter (ng\*h/mL)
| ng*h/mL | Apixaban, 10 mg (Whole Tablets) | Apixaban, 10 mg (Crushed and Suspended in Water) | Apixaban, 10 mg (Crushed and Mixed With Applesauce) |
|---|---|---|---|
| Adjusted Geometric Mean of Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Apixaban | 2461 (2273 to 2664) | 2528 (2375 to 2692) | 2055 (1915 to 2206) |
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Last Quantifiable Concentration \[AUC (0-T)\] is measured as nanograms multiplied by hours per milliliter (ng\*h/mL)
| ng*h/mL | Apixaban, 10 mg (Whole Tablets) | Apixaban, 10 mg (Crushed and Suspended in Water) | Apixaban, 10 mg (Crushed and Mixed With Applesauce) |
|---|---|---|---|
| Adjusted Geometric Mean of Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban | 2423 (2238 to 2623) | 2488 (2336 to 2651) | 2015 (1876 to 2165) |
Adverse Event (AE) = any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Serious Adverse Event (SAE)= a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
| participants | Apixaban, 10 mg (Whole Tablets) | Apixaban, 10 mg (Crushed and Suspended in Water) | Apixaban, 10 mg (Crushed and Mixed With Applesauce) |
|---|---|---|---|
| Deaths | 0 | 0 | 0 |
| SAEs | 0 | 0 | 0 |
| Drug-related AEs | 0 | 1 | 0 |
| Discontinuation due to AE | 0 | 1 | 0 |
Time of maximum observed plasma concentration (Tmax) measured in hours (h)
| hours | Apixaban, 10 mg (Whole Tablets) | Apixaban, 10 mg (Crushed and Suspended in Water) | Apixaban, 10 mg (Crushed and Mixed With Applesauce) |
|---|---|---|---|
| Time of Maximum Observed Plasma Concentration (Tmax) of Apixaban | 2.00 (1.00 to 5.00) | 2.00 (0.583 to 4.00) | 2.00 (1.00 to 4.00) |
Terminal plasma half-life (T-HALF) was derived from plasma concentration versus time data. T-HALF was the time required for one half of the total amount of administered drug to be eliminated from the body.
| hours | Apixaban, 10 mg (Whole Tablets) | Apixaban, 10 mg (Crushed and Suspended in Water) | Apixaban, 10 mg (Crushed and Mixed With Applesauce) |
|---|---|---|---|
| Terminal Plasma Half-life (T-HALF) of Apixaban | 12.4 ± 5.39 | 12.2 ± 5.19 | 12.5 ± 5.05 |
Frel is calculated using the treatment ratio of AUC(INF) where the denominator is the AUC(INF) of the reference therapy, 10mg of Apixaban (whole tablet).
| ratio | Apixaban, 10 mg (Crushed and Suspended in Water) | Apixaban, 10 mg (Crushed and Mixed With Applesauce) |
|---|---|---|
| Relative Bioavailability (Frel) of Apixaban | 1.03 ± 24 | 0.836 ± 20 |
Collected over Day 1 to May 2014; approximately 6 weeks F. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Apixaban, 10 mg (Whole Tablets) | — | 0/32 (0%) | 0/32 (0%) |
| Apixaban, 10 mg (Crushed and Suspended in Water) | — | 0/33 (0%) | 0/33 (0%) |
| Apixaban, 10 mg (Crushed and Mixed With Applesauce) | — | 0/32 (0%) | 0/32 (0%) |
All randomized participants
| Age, Continuous(years) | Apixaban, 10 mg (Whole Tablets) |
|---|---|
| Mean | 32.3 ± 7.35 |
| Sex: Female, Male(Participants) | Apixaban, 10 mg (Whole Tablets) |
|---|---|
| Female | 7 |
| Male | 26 |
| Weight(kilograms) | Apixaban, 10 mg (Whole Tablets) |
|---|---|
| Mean | 77.40 ± 7.933 |
| Height(centimeters) | Apixaban, 10 mg (Whole Tablets) |
|---|---|
| Mean | 172.13 ± 8.322 |
| Body Mass Index (BMI)(kilograms per meter^2) | Apixaban, 10 mg (Whole Tablets) |
|---|---|
| Mean | 26.14 ± 2.166 |
No study locations are listed for this record.
The record gives a start of Mar 2014, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban